iBio Faces NYSE American Delisting Threat
Ticker: IBIO · Form: 8-K · Filed: Aug 1, 2025 · CIK: 1420720
| Field | Detail |
|---|---|
| Company | Ibio, Inc. (IBIO) |
| Form Type | 8-K |
| Filed Date | Aug 1, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, stock-exchange
Related Tickers: IBIO
TL;DR
NYSE American might kick iBio off the exchange, they have 10 days to fix it.
AI Summary
On July 29, 2025, iBio, Inc. filed an 8-K report indicating a potential delisting from the NYSE American. The company received a notice from the exchange regarding its failure to meet continued listing standards. iBio has 10 business days to submit a compliance plan.
Why It Matters
This filing signals potential financial distress or operational challenges for iBio, Inc., which could impact its stock value and ability to raise capital.
Risk Assessment
Risk Level: high — Receiving a delisting notice from a major stock exchange indicates significant non-compliance with listing requirements, posing a substantial risk to the company's operations and investor confidence.
Key Numbers
- 10 business days — Compliance Period (Timeframe to submit a compliance plan to the NYSE American.)
Key Players & Entities
- iBio, Inc. (company) — Registrant
- NYSE American (company) — Stock Exchange
- July 29, 2025 (date) — Date of Report
FAQ
What specific continued listing standards did iBio, Inc. fail to meet?
The filing does not specify the exact continued listing standards that iBio, Inc. failed to meet, only that a notice was received from the NYSE American.
What is the deadline for iBio, Inc. to submit a compliance plan?
iBio, Inc. has 10 business days from the date of the notice to submit a compliance plan to the NYSE American.
What is the potential consequence if iBio, Inc. cannot regain compliance?
If iBio, Inc. cannot regain compliance with the NYSE American's listing standards, its securities may be delisted from the exchange.
Has iBio, Inc. previously received such notices?
The filing does not provide information on whether iBio, Inc. has previously received similar notices from the NYSE American.
What is the company's primary business?
iBio, Inc. is in the Pharmaceutical Preparations industry, as indicated by its Standard Industrial Classification code [2834].
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 1, 2025 regarding iBio, Inc. (IBIO).